NASDAQ: INBXInhibrx Biosciences Inc Stock Ownership - Who owns Inhibrx Biosciences?
Insider buying vs selling
Have Inhibrx Biosciences Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Jon Faiz Kayyem | Director | 2026-09-16 | 5,000 | $100.00 | $500.00kBuy |
| Kimberly Manhard | Director | 2026-09-15 | 500 | $105.05 | $52.53kSell |
| Kimberly Manhard | Director | 2026-09-14 | 500 | $110.26 | $55.13kSell |
| Kimberly Manhard | Director | 2026-09-11 | 500 | $111.78 | $55.89kSell |
| Kimberly Manhard | Director | 2026-09-09 | 500 | $115.80 | $57.90kSell |
| Mark Lappe | CEO | 2026-09-08 | 500 | $108.24 | $54.12kBuy |
| Mark Lappe | CEO | 2026-09-08 | 1,219 | $111.88 | $136.38kBuy |
| Mark Lappe | CEO | 2026-09-08 | 9,681 | $112.28 | $1.09MBuy |
| Kimberly Manhard | Director | 2026-09-08 | 500 | $115.14 | $57.57kSell |
| Douglas Forsyth | Director | 2026-09-08 | 2,500 | $114.65 | $286.62kBuy |
INBX insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when INBX insiders and whales buy or sell their stock.
INBX Shareholders
What type of owners hold Inhibrx Biosciences Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Jon Faiz Kayyem | 14.46% | 2,128,092 | $222.88M | Insider |
| Mark Lappe | 13.22% | 1,945,961 | $203.80M | Insider |
| Inhibrx Inc | 7.87% | 1,157,926 | $121.27M | Insider |
| Brendan P. Eckelman | 3.22% | 473,888 | $49.63M | Insider |
| Douglas Forsyth | 3.07% | 451,628 | $47.30M | Insider |
| Viking Global Investors LP | 0.70% | 102,864 | $10.77M | Insider |
| Kristiina Md Vuori | 0.14% | 20,443 | $2.14M | Insider |
| Kimberly Manhard | 0.05% | 7,500 | $785.48k | Insider |
| Morsta | 0.01% | 1,308 | $136.99k | Institution |
| Morgan Stanley | 0.01% | 1,308 | $136.99k | Institution |
INBX vs Biotech Stocks
Inhibrx Biosciences Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.